| Autor: |
Hussain Abdulrahman Al-Omar, Abdulaziz Abdulhadi Attuwaijri, Ibrahim Abdulrahman Aljuffali |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Saudi Pharmaceutical Journal, Vol 28, Iss 6, Pp 662-668 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
1319-0164 |
| DOI: |
10.1016/j.jsps.2020.04.006 |
| Popis: |
Saudi Arabia is undergoing a massive healthcare transformation to fulfill its new, national “Vision 2030.” To align with this objective, Saudi Arabia is establishing a new, independent and evidence-based health technology assessment (HTA) entity to help it maximize health gains through efficient use of resources. This study was designed to ascertain how pharmaceutical companies perceive the creation of such a national HTA entity in Saudi Arabia; what they think about it and expect from it. To achieve the study’s aim, we held a workshop in Riyadh, Saudi Arabia, lasting four and a half hours and hosted by the Saudi Ministry of Health (MOH). We invited 16 market access directors and managers from different multinational pharmaceutical companies to discuss the establishment of a national HTA entity. The findings from the workshop were structured around three axes: vision and remit; HTA method; and implementation and practical considerations. Overall, the pharmaceutical company participants were positive about HTA’s value for the Saudi healthcare system and expressed willingness to adapt to meet its future requirements. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
